Literature DB >> 27544696

Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers.

Theodore J Cicero1, Matthew S Ellis2, Zachary A Kasper2.   

Abstract

Physicians are frequently thought to be a major source of opioids diverted for non-therapeutic purposes, largely because it is so difficult for them to discern which patients might abuse them. In this study we sought to determine whether those who were first exposed to an opioid through a physician's prescription, and subsequently developed a substance use disorder, had a history of using psychoactive drugs prior to abusing opioids. Patients entering one of 125 drug treatment programs across the country for opioid abuse were asked to provide detailed histories of psychoactive drug use prior to their initial opioid exposure. Nearly half (47.1%, N=4493) indicated they were first exposed to opioids through a prescription from their physician to treat pain. Of these, 94.6% indicated experience with at least one other psychoactive substance (mean=4.55±0.05) prior to, or coincident with, their first exposure to an opioid from a physician. Alcohol (92.9%), nicotine and/or tobacco (89.5%), and marijuana (87.4%) were used by nearly all patients prior to, or coincident with, their first opioid prescription. If one excludes these drugs, 70.1% (N=2913) still reported some psychoactive drug use of licit or illicit stimulants (77.8%), benzodiazepines (59.8%) or hallucinogens (55.2%). Our results indicate that pain patients who developed a substance use disorder were rarely drug naïve prior to receiving their first opioid prescription. Rather, most have an extensive history of psychoactive drug use. As such, physicians should routinely ascertain complete licit and illicit drug histories in patients for whom they prescribe opioids. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug naïve; Iatrogenic abuse; Opioid abuse; Prescription opioids

Mesh:

Substances:

Year:  2016        PMID: 27544696     DOI: 10.1016/j.addbeh.2016.08.024

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  6 in total

1.  Complexities in understanding and addressing the serious public health issues related to the nonmedical use of prescription drugs.

Authors:  Amelia M Arria; Wilson M Compton
Journal:  Addict Behav       Date:  2016-09-09       Impact factor: 3.913

2.  Use of Tramadol or Other Analgesics in Patients Treated in the Emergency Department as a Risk Factor for Opioid Use.

Authors:  Jorge Enrique Machado-Alba; Laura Sofía Serna-Echeverri; Luis Fernando Valladales-Restrepo; Manuel Enrique Machado-Duque; Andrés Gaviria-Mendoza
Journal:  Pain Res Manag       Date:  2020-11-20       Impact factor: 3.037

3.  Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action.

Authors:  Olufunso M Agbalajobi; Theresa Gmelin; Andrew M Moon; Wheytnie Alexandre; Grace Zhang; Walid F Gellad; Naudia Jonassaint; Shari S Rogal
Journal:  PLoS One       Date:  2021-12-17       Impact factor: 3.240

Review 4.  Comparison of in vitro and in vivo Toxicity of Bupivacaine in Musculoskeletal Applications.

Authors:  Jasper G Steverink; Susanna Piluso; Jos Malda; Jorrit-Jan Verlaan
Journal:  Front Pain Res (Lausanne)       Date:  2021-08-20

5.  The Impact of Intentionality of Injury and Substance Use History on Receipt of Discharge Opioid Medication in a Cohort of Seriously Injured Black Men.

Authors:  Shoshana V Aronowitz; Sara F Jacoby; Peggy Compton; Justine Shults; Andrew Robinson; Therese S Richmond
Journal:  J Racial Ethn Health Disparities       Date:  2020-10-14

6.  Pain Acceptance Creates an Emotional Context That Protects against the Misuse of Prescription Opioids: A Study in a Sample of Patients with Chronic Noncancer Pain.

Authors:  Rosa Esteve; Estefanía Marcos; Ángela Reyes-Pérez; Alicia E López-Martínez; Carmen Ramírez-Maestre
Journal:  Int J Environ Res Public Health       Date:  2021-03-16       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.